Elan Corp., Plc. and Wyeth decided to stop the ongoing clinical trails testing effect of 2.0 mg/kg dose of experimental Alzheimer's drug bapineuzumab.
Officials from both companies declared the discontinuation of the highest of the three dosing regimens, 2.0 mg/kg, in the two ongoing Phase 3 studies of bapineuzumab in patients with mild-to-moderate Alzheimer's disease, or AD, who do not carry the Apolipoprotein E4, or ApoE4, allele. However testing of the 0.5 mg/kg and 1.0 mg/kg doses in two Phase III trials will continue as planned.